BioSpace News Archive

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the second quarter ended June 30, 2022.

CorMedix Inc. announced updates related to the FDA review of the DefenCath New Drug Application as well as other manufacturing and commercial updates.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its second quarter 2022 financial results and business highlights.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the second quarter ended June 30, 2022.

Rhythm Pharmaceuticals, Inc. announced that on August 2, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 63,035 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 38,690 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 24,345 shares of its common stock.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – announced financial results for the second quarter ended June 30, 2022.

Design Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, highlighted anticipated upcoming milestones across its clinical and research-stage pipeline of novel GeneTAC™ small molecules and reported second quarter 2022 financial results.

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2022.

In its business update today for the second quarter of 2022, Vaxart, Inc. (NASDAQ: VXRT) said it has begun working on vaccine candidate constructs that directly target new omicron variants of concern and is preparing to release top-line data in the third quarter of 2022 from its Phase II COVID-19 testing of a Wuhan strain vaccine construct.